No black box warning on record for Testopel

As of the latest FDA labeling reviewed, Testopel (TESTOSTERONE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Testopel medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis. In this case, the drug should be discontinued. Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms including hepatocellular carcinoma (see PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility). Peliosis he

No black box warning on record for Testopel

Other warnings & precautions

WARNINGS In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis. In this case, the drug should be discontinued. Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms including hepatocellular carcinoma (see PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility). Peliosis he

Testopel Black Box Warning

No black box warning on record for Testopel

Other warnings & precautions

Testopel Black Box Warning

No black box warning on record for Testopel

Other warnings & precautions